Pegfilgrastim: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Pegfilgrastim. Educational only — not medical advice.
Labeled uses
Patients with Cancer Receiving Myelosuppressive Chemotherapy NYVEPRIA is indicated in adults and pediatric patients aged newborn and older to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia [see Dosage and Administration (2.1) and Clinical Studies (14) ] .
Source: FDA labeling via NIH DailyMed (set 99d30b99…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.